Akari Therapeutics (AKTX) Registration Filing summary

Company overview and business model

• Focuses on developing next-generation antibody-drug conjugates (ADCs) with proprietary cancer-killing payloads, aiming to improve efficacy and safety in oncology treatments compared to current ADCs, which mostly use two standard payload classes.

• Lead candidate AKTX-101 targets Trop2, a protein highly expressed in various solid tumors, and is in preclinical development; pipeline also includes AKTX-102 and other ADCs pairing novel payloads with key cancer-targeting antibodies.

• Shifted strategic focus to ADCs after acquiring Peak Bio in November 2024, suspending internal development of legacy programs and seeking partners for their advancement.

Financial performance and metrics

• As of December 31, 2024, held approximately $2.6 million in cash and reported recurring operating losses, negative cash flows, and net capital deficiency, raising substantial doubt about ability to continue as a going concern.

• Unaudited pro forma combined net loss for the year ended December 31, 2024, was $19.5 million, reflecting the merger with Peak Bio.

• No product sales to date and not expecting revenue from product sales in the foreseeable future.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of ADSs by selling shareholders; may receive up to $18.3 million if all warrants are exercised for cash.

• Any warrant exercise proceeds will be used for research and development, general and administrative expenses, and working capital.